Iressa launched for lung cancer

Iressa (gefitinib) is a new treatment for locally advanced or metastatic non-small cell lung cancer with activating mutations of EGFR-TK.

Gefitinib is an antagonist of the epidermal growth factor receptor tyrosine kinase (EGFR-TK). In cancer cells, EGFR-TK-activating mutations contribute to cell survival, proliferation and metastasis.

Physicians should assess EGFR mutation status before administering gefinitib, as there is no evidence that the drug is effective in patients whose tumours lack EGFR mutations.

Interstitial lung disease is common in gefitinib-treated patients and can be severe; if this complication develops, the drug should be discontinued.

View Iressa drug record

Further information: AstraZeneca

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more